目的:青蒿素及其衍生物,从中药中提取的著名抗疟疾药物,与治疗纤维化疾病有关。然而,青蒿素在心力衰竭的发病机制中是否会影响心脏纤维化尚不清楚。本研究旨在评估青蒿素对心力衰竭模型心功能和心肌纤维化的可能影响,并探讨其潜在机制。
方法:皮下注射异丙肾上腺素以诱导心脏纤维化模型。青蒿素治疗4四周后进行蛋白质组分析。超声心动图用于评估心功能和结构。苏木精和伊红(H&E)染色,以及Masson染色,进行了组织病理学检查。α-SMA,胶原蛋白I,免疫组化染色检测心肌中III的表达。心脏重量(HW)与体重之比(HW/BW,mg/kg)和心脏重量与胫骨长度的比率(HW/TL,mg/mm)作为心脏重塑的指标。使用酶联免疫吸附测定(ELISA)定量大鼠血浆中的脑钠肽(BNP)水平。相比之下,通过蛋白质印迹分析评估心肌和成纤维细胞中TGF-β1,p-Smad2/3和Smad2/3的蛋白水平.Col-I的RT-qPCR分析,Col-III,α-SMA,NLRP3,Caspase-1,IL-1β,IL-18在心脏进行。
结果:蛋白质组学分析鉴定出227种差异表达蛋白(DEPs),包括119个上调蛋白和108个下调蛋白。这些蛋白被鉴定为青蒿素靶向的用于改善心肌重塑的核心蛋白。DEP的GO注释表明DEP主要与TGF-β和NLRP3炎性体调节等生物学过程有关。异丙肾上腺素诱导SD大鼠心脏重构模型的体内研究,我们发现,青蒿素通过抑制TGFβ-1/Smads信号传导和抑制NLRP3炎性体激活,显著改善了心功能障碍并减少了胶原蛋白的产生.通过下调α-SMA的表达,Col-I,还有Col-III,NLRP3,IL-1β,IL-18,Caspase-1mRNA,和心肌中的TGF-β1,p-SMAD2/3蛋白。在TGF-β1处理的原代心脏成纤维细胞中一致观察到青蒿素的类似有益作用。
结论:青蒿素通过TGF-β1/Smad2/3通路和NLRP3炎性体缓解心肌重构。。
OBJECTIVE: Artemisinin and its derivatives, the well-known anti-malarial drugs extracted from traditional Chinese medicine, have been implicated in treating fibrotic diseases. However, whether artemisinin affects cardiac fibrosis in the pathogenesis of heart failure is still unknown. This study aimed to evaluate the possible effects of artemisinin on cardiac function and myocardial fibrosis in the heart failure model and to explore the underlying mechanisms.
METHODS: Isoproterenol was injected subcutaneously for induction of the cardiac fibrosis model. Proteomic analysis was performed after 4 four weeks of artemisinin treatment. Echocardiography was used to evaluate cardiac function and structure. Hematoxylin and eosin (H&E) staining, as well as Masson staining, were performed for histopathology. The α-SMA, collagen I, and III expression in the myocardium was detected by Immunohistochemical staining. The ratio of heart weight (HW) to body weight (HW/BW, mg/kg) and the ratio of heart weight to tibia length (HW/TL, mg/mm) were calculated as indicators for cardiac remodeling. Brain natriuretic peptide (BNP) levels were quantified in rat plasma using enzyme-linked immunosorbent assay (ELISA). In contrast, the protein levels of TGF-β1, p-Smad2/3, and Smad2/3 were assessed in myocardium and fibroblasts via western blot analysis. RT-qPCR analysis of Col-I, Col-III, α-SMA, NLRP3, Caspase-1, IL-1β, and IL-18 was performed in the heart.
RESULTS: Proteomic analysis identified 227 differentially expressed proteins (DEPs), including 119 upregulated and 108 downregulated proteins. These proteins were identified as the core proteins targeted by artemisinin for improving myocardial remodeling. GO annotation of the DEPs indicated that the DEPs were mainly associated with biological processes such as TGF-β and NLRP3 inflammasome regulation. In the in vivo study of an isoproterenol-induced SD rat cardiac remodeling model, we found that artemisinin administration significantly ameliorated cardiac dysfunction and reduced collagen production by suppressing TGFβ-1/Smads signaling and inhibiting NLRP3 inflammasome activation. As manifested by downregulating the expression of α-SMA, Col-I, and Col-III, NLRP3, IL-1β, IL-18, Caspase-1 mRNA, and TGF-β1, p-SMAD 2/3 protein in the myocardium. Similar beneficial effects of artemisinin were consistently observed in TGF-β1 treated primary cardiac fibroblasts.
CONCLUSIONS: Artemisinin relieves myocardial remodeling through TGF-β1/Smad2/3 pathway and NLRP3 inflammasome..